| Target |
Advantages |
Drawbacks |
Preliminary data |
| Neisseria Adhesin A- NadA |
Predicted molecular structure strikingly similar to the known virulence-associated. |
Based only in one antigen. |
Is capable of generating local and systemic cellular and humoral immunity when coadministered with mucosal adjuvants [26,52,53]. |
| Surface Porin - PorA |
N. meningitidis strains express usually only one kind of porin class. |
Vaccines based on this porin are effective only against clonal epidemics |
Effective only against clonal epidemics [25,54]. |
| Outer membrane vesicule - OMV MenBvac |
vaccine consists of several recently discovered, relatively conserved surface antigens, NadA, fHBP, and NHBA, and a PorA |
Protected only against homologous meningococal strains. |
All four doses of MenBvac are safe, no serious adverse events occurred [58,59]. |
| rMenB-OMV -recombinant MenB with OMV |
vaccine consists of several recently discovered, relatively conserved surface antigens, NadA, fHBP, and NHBA, and a PorA |
Protected only against homologous meningococal strains. |
Clinical trials revealed that vaccinated individuals produce bactericidal antibodies, which protect against infection with homologous meningococcal strains [55,56]. |
| Intranasal Neisseria OMVB |
Intranasal vaccination with OMV, presenting complex antigens mixture. |
Still in trials. |
Immunogenicity and safety of a group B vaccine proved. [60]. |
